LLY is trading 3% down at $1092.74 as investors lock in gains following a sharp rally driven by positive obesity-drug developments.
- The pullback comes after France approved reimbursement for Mounjaro and CVS Health restored coverage for Zepbound.
- Shares are undergoing consolidation after hitting a series of record highs in recent trading sessions.
- Market participants are taking profits despite the continued positive news flow regarding Eli Lilly's weight-loss portfolio.